Ellen Kuenzig M, Windsor Joseph W, Barrett Lisa, Bernstein Charles N, Bitton Alain, Carroll Matthew W, Chauhan Usha, Coward Stephanie, Fowler Sharyle, Ghia Jean-Eric, Geist Rose, Gibson Deanna L, Graff Lesley A, Griffiths Anne M, Guoxian Huang James, Jones Jennifer L, Khanna Reena, Lakatos Peter L, Lee Kate, Mack David R, Marshall John K, Mukhtar Mariam S, Murthy Sanjay K, Nguyen Geoffrey C, Panaccione Remo, Seow Cynthia H, Singh Harminder, Tandon Parul, Targownik Laura E, Zelinsky Sandra, Benchimol Eric I, Kaplan Gilaad G
SickKids Inflammatory Bowel Disease Centre, Division of Gastroenterology, Hepatology and Nutrition, The Hospital for Sick Children, Toronto, Ontario, Canada.
Child Health Evaluative Sciences, SickKids Research Institute, Toronto, Ontario, Canada.
J Can Assoc Gastroenterol. 2021 Nov 5;4(Suppl 2):S1-S9. doi: 10.1093/jcag/gwab027. eCollection 2021 Dec.
Persons with inflammatory bowel disease (IBD) make up more than 0.75% of the Canadian population in 2021. Early in the COVID-19 pandemic, individuals with IBD, particularly those on immunosuppressive therapies, were concerned that their health status may place them at higher risk of contracting COVID-19 or experiencing more severe disease course if infected with SARS-CoV-2. In response, Crohn's and Colitis Canada developed the COVID-19 and IBD Taskforce in March 2020 to rapidly synthesize the evolving knowledge of COVID-19 as relevant to Canadians with IBD. The Taskforce communicated expert information directly to the Canadian IBD community through online tools and a webinar series. In order to understand the full impact of COVID-19 on the IBD community, Crohn's and Colitis Canada commissioned a policy report that was informed through a systematic literature review and synthesized across working groups along the following domains: Epidemiology, Children and Expectant Mothers with IBD, Seniors with IBD, Mental Health, Risk Factors and Medications, Vaccines, and Healthcare Delivery during the Pandemic and the Future Model of IBD Care. This report from Canadian physicians, researchers, and IBD community representatives highlights the physical, mental, and health systems impact of COVID-19 on the entire spectrum of the IBD community, including children, adolescents, adults, seniors, and pregnant people with IBD. This executive summary provides an overview of the crucial information from each of the chapters of the policy report, supplemented with additional information made available through Crohn's and Colitis Canada's webinar-based knowledge translation platform.
2021年，炎症性肠病（IBD）患者占加拿大人口的比例超过0.75%。在2019冠状病毒病大流行初期，患有IBD的人，尤其是那些接受免疫抑制治疗的人，担心他们的健康状况可能使他们感染2019冠状病毒病的风险更高，或者如果感染了严重急性呼吸综合征冠状病毒2（SARS-CoV-2），可能会经历更严重的病程。作为回应，加拿大克罗恩病和结肠炎协会于2020年3月成立了2019冠状病毒病与IBD特别工作组，以迅速整合与患有IBD的加拿大人相关的、不断发展的2019冠状病毒病知识。该特别工作组通过在线工具和一系列网络研讨会，将专家信息直接传达给加拿大IBD群体。为了了解2019冠状病毒病对IBD群体的全面影响，加拿大克罗恩病和结肠炎协会委托撰写了一份政策报告，该报告通过系统的文献综述提供信息，并在以下领域的各工作组中进行综合：流行病学、患有IBD的儿童和孕妇、患有IBD的老年人、心理健康、风险因素和药物、疫苗，以及大流行期间的医疗服务提供和IBD护理的未来模式。这份来自加拿大医生、研究人员和IBD群体代表的报告强调了2019冠状病毒病对IBD群体全谱系的身体、心理和卫生系统影响，包括患有IBD的儿童、青少年、成年人、老年人和孕妇。本执行摘要概述了政策报告各章的关键信息，并补充了通过加拿大克罗恩病和结肠炎协会基于网络研讨会的知识转化平台提供的其他信息。
